MARAVAI LIFESCIENCES HOLDINGS INC (MRVI)
Health Care · Life science reagents and contract manufacturing · NASDAQ
Maravai LifeSciences produces critical reagents and manufacturing services for mRNA vaccines and therapies, with CleanCap and TriLink products serving large biotech and pharmaceutical customers.
What MARAVAI LIFESCIENCES HOLDINGS INC does
Maravai LifeSciences provides life science reagents, custom synthesis services, and manufacturing capabilities for the research, development, and commercial production of vaccines and therapeutics. The company operates through TriLink (custom nucleotides and oligonucleotides), Cygnus (life science reagents), and CleanCap (a capping technology for mRNA vaccines and therapies). Its products enable pharmaceutical and biotechnology customers to manufacture mRNA-based vaccines and other advanced therapeutic modalities.
Themes: mRNA vaccines, synthetic biology, life science manufacturing, vaccine production, therapeutic manufacturing
Fundamentals
- Price$8.64 as of 2026-08-21 close
- Market cap$1.5B as of 2026-08-24
- 1-year return+261.5% 2025-08-21 close $2.39 → 2026-08-21 close $8.64
- P/En/a negative earnings
- Net margin-37.1% as of 2026-08-24
- Gross margin+34.9% as of 2026-08-24
- ROE-35.4% as of 2026-08-24
- Debt / equity0.86 as of 2026-08-24
- Revenue growth (YoY)-3.3% as of 2026-08-24
- Revenue CAGR (3y)-40.5% SEC XBRL
- Beta0.55 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How MRVI compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How MARAVAI LIFESCIENCES HOLDINGS INC looks technically
MARAVAI LIFESCIENCES HOLDINGS INC (MRVI) is trading 104.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 202 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 79, in overbought territory (above 70). MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive). It just made a new 20-day high, pushing above its recent trading range. It is 2.6% below its 52-week high (its highest price of the past year). Trading volume is running unusually high — about 2.8× its 30-day average, a sign of heightened interest.
Trend
7
| Distance from the 200-day | it is trading 104.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +104.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $6.26 | $6.26 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.24 | $4.24 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 202 trading days ago — a "golden cross", a bullish long-term signal | 202 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with buyers in control | 37.2 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 79, in overbought territory (above 70) | 79.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($5.41 to $8.87) — its "stochastic" reading is 93 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 93.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $8.87 | $8.87 |
|---|---|---|
| From the 52-week high | it is 2.6% below its 52-week high (its highest price of the past year) | -2.6% |
| Above the 52-week low | it is 278.9% above its 52-week low (its lowest price of the past year) | +278.9% |
| Below the 52-week high | it is 2.6% below its highest point of the past year | 2.6% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $63.55 (set on 2021-08-23) | $63.55 |
| Given back of the 52-week move | over the past year its closes ranged ($2.33 to $8.64), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.54 to $4.74. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 86.4% below its all-time high | -86.4% |
| Nearest price level | it is trading 13.7% above a support level at $7.46 — a price it turned at twice since 2024-10-10, most recently on 2026-07-23. Since 2024-08-21 it has 13 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -13.7% |
| All-time low | its lowest closing price on record is $1.67 (set on 2025-04-17) | $1.67 |
| Above the all-time low | it is 418.9% above its all-time low | +418.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.5051 between its high and its low — about 5.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.5051 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $4.93 and $8.06 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $4.93 – $6.50 – $8.06 |
| Typical daily range (% of price) | its price moves about 5.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.8% |
| Stretch from the 200-day average | it is trading 8.7 daily ranges above its 200-day average price (104.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 8.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 2.8× its 30-day average, a sign of heightened interest | 2.81× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.1% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.1% |
|---|---|---|
| Open gap | it gapped 3.1% above the previous close 1 session ago and has not traded back through the level it left behind at 7.22 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.0% |
| Gap filled | a 10.4% gap down opened on 2026-08-07 has been "filled" 10 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 10 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 4 sessions in a row, a +52.11% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 4 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 19.4 percentage points (the stock gained 21.7% while the market gained 2.3%) | +19.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 89.8 percentage points (the stock gained 92.9% while the market gained 3.1%) | +89.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 167.6 percentage points (the stock gained 178.7% while the market gained 11.1%) | +167.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 241.0 percentage points (the stock gained 261.5% while the market gained 20.5%) | +241.0% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 40% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 10.4% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +39.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 70% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $5.09 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +69.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 19% above the average price paid since it last reported on 2026-08-06 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $7.25 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +19.1% |
Price levels it has turned at before
MRVI last closed at $8.64 on 2026-08-21. Since 2024-08-21 it has turned at 13 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $7.46 | Support | 13.7% below the last close | turned there twice · 2024-10-10 to 2026-07-23 |
| $6.08 | Support | 29.6% below the last close | turned there three times · 2024-12-02 to 2025-01-28 |
| $5.04 | Support | 41.6% below the last close | turned there three times · 2024-12-06 to 2026-05-11 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Overbought (14-day RSI above 70) · Near the 52-week high · Unusually heavy trading volume · Broke out to a new 20-day high · Broke out to a new 20-day high on heavy volume | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.75 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$7.30 range $6.50 – $8.00; median $7.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MRVI
- Consensus EPS estimate-$0.09066 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High dependency on a limited number of customers for mRNA vaccine programs; revenue from CleanCap is subject to factors outside management control including vaccine program adoption rates and regulatory approvals","Operating results are prone to significant fluctuation due to volatility in customer spending and vaccine development cycles; recent organizational restructuring and workforce reductions create execution risk","Customer use of products in novel mRNA vaccine and therapy modalities exposes the company to regulatory risk, negative clinical outcomes, and potential obsolescence if alternative therapies are developed or regulatory scrutiny increases"]
What changed in the latest 10-Q
AI-assisted comparison of MRVI's 10-Q filed 2026-05-08 against the prior one filed 2025-11-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references Annual Report on Form 10-K for year ended December 31, 2025 (vs. December 31, 2024 in older filing)
- Newer filing states employment of 416 full-time employees as of March 31, 2026 (vs. over 550 as of September 30, 2025, then approximately 440 after reduction in force in older filing)
- Newer filing reports North America revenue percentage of 54.2% for Q1 2026 (vs. 60.1% for Q3 2025 in older filing)
- Newer filing reports total revenue of $65.8 million for Q1 2026 (vs. $41.6 million for Q3 2025 in older filing)
- Newer filing provides segment revenue breakdown using TriLink and Cygnus labels: TriLink $47.5 million, Cygnus $18.4 million for Q1 2026
- Newer filing reports SG&A expenses of $29.1 million for Q1 2026 (vs. $35.4 million for Q3 2025 in older filing)
- Newer filing reports R&D expenses of $3.9 million for Q1 2026 (vs. $3.8 million for Q3 2025 in older filing)
- Newer filing includes 'Recent Developments' section describing voluntary prepayment of $50.0 million on Term Loan in February 2026
- Newer filing states CleanCap revenue of $14.3 million in Q1 2026 and expects no further high-volume CleanCap orders for remainder of 2026
- Newer filing references $167.0 million Revolving Credit Facility in Adjusted EBITDA explanation
- Newer filing describes segments as TriLink and Cygnus (vs. Nucleic Acid Production and Biologics Safety Testing in older filing)
- Removed:
- Older filing's statement that company was incorporated in August 2020 and description of Organizational Transactions and holding company structure removed from newer filing
- Older filing's reference to non-controlling interest in Topco LLC removed from newer filing
- Older filing's description of 2025 Corporate Realignment Plan and reduction in force removed from newer filing
- Older filing's 'Restatement of Previously Issued Financial Statements' section discussing $3.9 million revenue recognition error in 2024 removed from newer filing
- Older filing's nine-month financial results and comparisons (September 30, 2025 vs. 2024) removed from newer filing
- Older filing's reference to acquiring customers from 'top global biopharmaceutical companies ranked by research and development expenditures according to industry experts' removed from newer filing
- Reworded:
- Newer filing states company 'provides products and services supporting the development and manufacture of drug therapies, diagnostics, vaccines and cell and gene therapies' vs. older filing's 'providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases'
- Newer filing describes products as 'complex nucleic acids and enzymes for therapeutic and diagnostic applications' vs. older filing's 'complex nucleic acids for diagnostic and therapeutic applications'
- Newer filing states 'Cygnus provides biologics safety testing products and services' vs. older filing's 'immunoassay, qPCR and mass spectrometry-based products and services' description
- Newer filing uses 'qpCR' formatting vs. older filing's 'qPCR'
- Newer filing's segment names changed from 'Nucleic Acid Production and Biologics Safety Testing' to 'TriLink and Cygnus'
- Newer filing states 'We continue to focus resources on supporting our core business segments' vs. older filing's 'We focus a substantial portion of our resources on supporting our core business segments'
- Newer filing removed detailed language about 'fostering strong relationships with both existing and new customers and distributors' and management team experience that appeared in older filing
- Newer filing states R&D 'We intend to continue investing in research and development' vs. older filing's 'We intend to continue to invest in research and development and new products and technologies'
- Notes:
- Older filing text is truncated at end ('Relevant restated financial information is included in Note 18 of the Annual Report on Form 10-K filed with the SEC on March 18, 2025. As part of t'), limiting completeness of comparison
- Newer filing text is also truncated at end ('Components of Resu'), limiting completeness of comparison
- The two filings cover different fiscal periods (Q1 2026 vs. Q3 2025) and use different segment naming conventions, making some comparisons contextual rather than direct
Risk Factors
- Added:
- Our use of Artificial Intelligence technologies, including Machine Learning, and business, compliance, and reputational challenges that may result from such use. (added in 2026-05-08 filing)
- Removed:
- The level of our customers' spending on and demand for outsourced nucleic acid production and biologics safety testing products and services. (removed; replaced with TriLink and Cygnus reference in 2026-05-08)
- The risk that we do not realize the expected operational or financial benefits from our organizational changes. (removed in 2026-05-08 filing)
- Decreases in research and development funding caused by changes in U.S. public health policy and the spending priorities of the U.S. federal government. (removed in 2026-05-08 filing)
- Risks and uncertainty related to the restatement of our previously issued financial statements. (removed in 2026-05-08 filing)
- Our ability to remediate the material weaknesses in our internal control over financial reporting in a timely manner. (removed in 2026-05-08 filing)
- Reworded:
- The level of our customers' spending on and demand for: changed from 'outsourced nucleic acid production and biologics safety testing products and services' to 'TriLink and Cygnus products and services' (2026-05-08 filing)
- Natural disasters, geopolitical instability: changed from 'including the ongoing military conflicts in Ukraine and the Middle East' to 'including ongoing military conflicts' (2026-05-08 filing)
- Risks related to our acquisitions: removed phrase 'integration and' before 'whether we achieve the anticipated benefits' (2026-05-08 filing)
- Notes:
- Text in both filings appears truncated at the end, preventing complete comparison of all risk factors
- Page number references differ (37 vs. 61 for Item 1A in older filing), suggesting different document lengths overall
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 2 sells ($254000) — 1 selling insider
- Last 180 days0 buys · 2 sells ($254000) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-10. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about MRVI's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding MRVI as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 17,681,972
- Reported value $50,039,978
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
MRVI had 8,510,416 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for MRVI because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 8,510,416
- Prior settlement (shares) 9,271,035
- Reported change -8.2%
- Days to cover (reported) 3.63
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Chemgenes Corporation
- ChemRNA
- Cytiva (Cytiva Life Sciences)
- Lonza
- Evonik
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Frequently asked questions
What does MARAVAI LIFESCIENCES HOLDINGS INC (MRVI) do?
Maravai LifeSciences provides life science reagents, custom synthesis services, and manufacturing capabilities for the research, development, and commercial production of vaccines and therapeutics. The company operates through TriLink (custom nucleotides and oligonucleotides), Cygnus (life science reagents), and CleanCap (a capping technology for mRNA vaccines and therapies).
What sector is MARAVAI LIFESCIENCES HOLDINGS INC (MRVI) in?
MARAVAI LIFESCIENCES HOLDINGS INC (MRVI) is classified in the Health Care sector. Its industry is Life science reagents and contract manufacturing. It trades on NASDAQ.
Who are MARAVAI LIFESCIENCES HOLDINGS INC's (MRVI) competitors?
Notable peers of MARAVAI LIFESCIENCES HOLDINGS INC (MRVI) include Chemgenes Corporation, ChemRNA, Cytiva (Cytiva Life Sciences), Lonza and Evonik. This peer set is informational only — not financial advice.
Is MARAVAI LIFESCIENCES HOLDINGS INC (MRVI) overbought or oversold right now?
MARAVAI LIFESCIENCES HOLDINGS INC (MRVI) is currently in overbought territory (its 14-day RSI is 79, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MRVI come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.